LSK Global PS Attends DIA 2018 and Solidifies Its Position as Leading Korean CRO

-    Dr. Young-Jack Lee, CEO of LSK Global PS, is the first Korean member to join a panel discussion at the DIA 2018 Global Annual Meeting where he shared his view on the current state of clinical trials as well as how to increase patient engagement in Korea.      

-    LSK Global PS established a global partnership, attracting visitors to a joint exhibit booth with the ACA and a booth dedicated to the company’s data management and pharmacovigilence services.

[June 28, 2018] Korea’s leading contract research organization (CRO) LSK Global Pharma Services Co., Ltd. (LSK Global PS) announced that the company’s CEO, Young-Jack Lee, attended the DIA 2018 Global Annual Meeting held in Boston, the U.S. from June 24 through 28, 2018. He was the first Korean member to join a panel discussion at the annual meeting where he shared his view on the background of Korea’s rise to a leading position in global clinical trials as well as ways to increase patient engagement in clinical trials. In addition, the company had two booths at the annual meeting, expanding its presence in the global clinical trial market while solidifying its position as a leading Korean CRO.

The DIA Global Annual Meeting, established by the Drug Information Association 54 years ago, is one of the largest and most prestigious events in the pharmaceutical industry in the U.S. It is designed to foster the international exchange of insights to improve health globally through the advancement of lifesaving medicines and technologies. This year, the gathering attracted more than 7,000 professionals who came from more than 450 pharmaceutical, biotechnology and medical device companies in about 50 countries around the globe.

Photo 1. LSK Global PS CEO Young-Jack Lee joins panel discussions at the “Global Perspectives on Patient Engagement” session during the DIA 2018 Global Annual Meeting

Dr. Young-Jack Lee, CEO of LSK Global PS, took part in a panel discussion at a session titled “Global Perspectives on Patient Engagement” on June 26, 2018. The panelists discussed drug development and regulations in Asia and Latin America with a focus on the current state of and future directions for patient engagement. Dr. Lee’s presentation touched on the environment and the background of Korea’s rise to a leading position in global clinical trials despite being a latecomer to the area. He said that the level of patient engagement in Korea has reached that of industrialized countries as evidenced by drug use exemptions for clinical trials and emerging site management organizations (SMOs) in the country. On the other hand, even with the efforts to increase patient engagement, there are still obstacles to sending healthcare professionals to sites, according to Lee, who then, shared his view on what changes need to be made in patient engagement so as to maximize the benefits of clinical trials in Korea.

Lee’s participation in the panel is significant given that he was the first Korean penalist at the DIA Global Annual Meeting. It was also a good opportunity to show Korea’s rise and competence in global clinical trials of innovative drugs as Lee participated in the panel discussion as a representative of a leading CRO from Korea.

   

Photo 2 & 3. ACA Booth (left) and LSK Global PS Booth (right) at the DIA 2018 Global Annual Meeting

Throughout the five-day period, LSK Global PS attracted visitors to its joint booth with the Asia CRO Alliance (ACA) and another booth dedicated to the company’s clinical data mangement and pharmacovigilence services. The ACA is an association of CROs in the Asia region. It helps members, which are local CROs that are highly specialized with extensive local knowledge, to make timely decision and be more flexible in responding to sponsors’ demands when conducting clinical trials to ensure that they are able to provide more efficient clinical trial service. The association consists of CROs in six countries, including Japan, Vietnam, Malaysia, Taiwan and the Philippines as well as LSK Global PS in Korea. As the main contact company at the ACA booth, LSK Global PS promoted the clinical trial markets of Asian countries and the experience of the local CROs, inviting global and multinational pharmaceutical companies to conduct clinical trials in Korea and Asia.

In addition, LSK Global PS showcased its clinical data mangement and pharmacovigilance services at a dedicated booth for the third straight year. Data management and drug safety information management are considered the pivotal area in drug development and the core competency of the CRO industry. LSK Global PS’ CDM and PV teams have been recognized for their partnerships with medical product companies and CROs across the world as well as ongoing efforts to provide top quality services and clinical trial data which meet global criteria as they have become the best data headquarters in Asia.     

“I am privileged and pleased to attend the DIA 2018 Global Annual Meeting and to be the first Korean panelist to take part in discussions with professionals from countries across the world, seeing that Korea has grown to be an equal partner on the global stage.” Said Dr. Young-Jack Lee, CEO of LSK Global PS. “We remain committed to further expanding our partnerships based on the potential of the clinical trial market in Asia and LSK Global PS’s top quality services, including our clinical trial data services, which we showcased at our booths during the meeting.”